Real-World Safety of Tepotinib: Insights from the Food and Drug Administration Adverse Event Reporting System
December 2025
in “
PLoS ONE
”
Studysummary This study evaluated the real-world safety of Tepotinib for treating NSCLC with METex14 skipping mutations, confirming known adverse events and identifying new signals like deafness and taste disorder, especially highlighting early monitoring.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on journals.plos.org →